AR083946A1 - Metodos de tratamiento con inhibidores selectivos de bcl-2 - Google Patents
Metodos de tratamiento con inhibidores selectivos de bcl-2Info
- Publication number
- AR083946A1 AR083946A1 ARP110104338A ARP110104338A AR083946A1 AR 083946 A1 AR083946 A1 AR 083946A1 AR P110104338 A ARP110104338 A AR P110104338A AR P110104338 A ARP110104338 A AR P110104338A AR 083946 A1 AR083946 A1 AR 083946A1
- Authority
- AR
- Argentina
- Prior art keywords
- heterocyclyl
- optionally substituted
- independently selected
- cycloalkyl
- bcl
- Prior art date
Links
- 229940124639 Selective inhibitor Drugs 0.000 title abstract 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 title 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 title 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- RVNZEJNWTUDQSC-JOCHJYFZSA-N (2r)-n-(6-aminohexyl)-1-tridecanoylpyrrolidine-2-carboxamide Chemical compound CCCCCCCCCCCCC(=O)N1CCC[C@@H]1C(=O)NCCCCCCN RVNZEJNWTUDQSC-JOCHJYFZSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- 208000005777 Lupus Nephritis Diseases 0.000 abstract 1
- 208000021386 Sjogren Syndrome Diseases 0.000 abstract 1
- 230000001640 apoptogenic effect Effects 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 101150009274 nhr-1 gene Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos de tratamiento de lupus eritematoso sistémico, nefritis lúpica o síndrome de Sjogren con compuestos que inhiben selectivamente la actividad de las proteínas anti apoptóticas BcI 2.Reivindicación 2: El método de la reivindicación 1, caracterizado porque el inhibidor selectivo de BcI-2 es un compuesto de fórmula (1), donde A1 es N o CH; B1 es OR1 o NHR1; Y1 es CN, NO2, CF3, F o Cl; R1 es (CH2)nR2; R2 es cicloalquilo o heterociclilo; donde los grupos heterociclilo y cicloalquilo están opcionalmente sustituidos con uno o más sustituyentes seleccionados en forma independiente entre R4, OR4, OH, CN, o F; R3 es heteroarilo; donde el grupo heteroarilo está opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre NH2, Cl, o F; R4 es alquilo, cicloalquilo, heterociclilo, o espiroheterociclilo; donde el grupo alquilo está opcionalmente sustituido con uno o más F; R5 es deuterio; cada R6 se selecciona en forma independiente entre CH3, espirociclopropilo y OH; m es 0, 1, 2, 3, 4, 5 ó 6; n es 0 ó 1; y p es 0, 1 ó 2; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41668910P | 2010-11-23 | 2010-11-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR083946A1 true AR083946A1 (es) | 2013-04-10 |
Family
ID=45218888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110104338A AR083946A1 (es) | 2010-11-23 | 2011-11-22 | Metodos de tratamiento con inhibidores selectivos de bcl-2 |
Country Status (36)
Country | Link |
---|---|
US (5) | US20120129853A1 (es) |
EP (2) | EP3028702B1 (es) |
JP (2) | JP5876067B2 (es) |
KR (3) | KR20190109590A (es) |
CN (2) | CN103402521B (es) |
AR (1) | AR083946A1 (es) |
AU (2) | AU2011332000B2 (es) |
BR (1) | BR112013012854B1 (es) |
CA (1) | CA2820618C (es) |
CL (1) | CL2013001458A1 (es) |
CR (1) | CR20130268A (es) |
CY (1) | CY1118442T1 (es) |
DK (1) | DK2642999T3 (es) |
DO (1) | DOP2017000056A (es) |
EC (1) | ECSP13012710A (es) |
ES (2) | ES2603129T3 (es) |
GT (1) | GT201300136A (es) |
HR (1) | HRP20161762T1 (es) |
HU (1) | HUE031267T2 (es) |
IL (2) | IL226490A (es) |
LT (1) | LT2642999T (es) |
MX (1) | MX346201B (es) |
MY (2) | MY165884A (es) |
NZ (2) | NZ708508A (es) |
PH (1) | PH12016500939B1 (es) |
PL (1) | PL2642999T3 (es) |
PT (1) | PT2642999T (es) |
RS (1) | RS55545B1 (es) |
RU (1) | RU2593231C2 (es) |
SG (2) | SG190399A1 (es) |
SI (1) | SI2642999T1 (es) |
TW (2) | TWI535701B (es) |
UA (2) | UA119150C2 (es) |
UY (1) | UY33746A (es) |
WO (1) | WO2012071374A1 (es) |
ZA (1) | ZA201303589B (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
CN103153311A (zh) | 2010-06-03 | 2013-06-12 | 药品循环公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
CA2811805A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
CN103402521B (zh) | 2010-11-23 | 2016-01-20 | 艾伯维巴哈马有限公司 | 使用选择性的bcl-2抑制剂的治疗方法 |
CN107266435A (zh) | 2010-11-23 | 2017-10-20 | Abbvie 公司 | 细胞凋亡诱导剂的盐和晶形 |
CA2859385A1 (en) | 2011-12-13 | 2013-06-20 | Buck Institute For Research On Aging | Methods for improving medical therapies |
EP2877598A1 (en) | 2012-07-24 | 2015-06-03 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
CN111481552A (zh) | 2012-09-07 | 2020-08-04 | 吉宁特有限公司 | II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗 |
US20150241429A1 (en) * | 2012-09-11 | 2015-08-27 | Hospital For Special Surgery | Irhom2 inhibition for the treatment of complement mediated disorders |
UY39847A (es) | 2013-03-13 | 2022-09-30 | Abbvie Ireland Unlimited Co | Procesos para la preparación de un agente inductor de la apoptosis |
US20140275082A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
SG10201805670QA (en) | 2014-01-28 | 2018-08-30 | Buck Inst Res Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
CA2942528A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics Inc. | Phospholipase c gamma 2 and resistance associated mutations |
EP3139942B1 (en) * | 2014-05-05 | 2019-12-18 | Bioventures, Llc | COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS |
EP3179991B1 (en) | 2014-08-11 | 2021-10-06 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor |
US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
CN108137550A (zh) | 2015-08-10 | 2018-06-08 | 达纳-法伯癌症研究所有限公司 | 对bet溴结构域抑制剂的抗性的机理 |
BR112018008882A8 (pt) | 2015-11-03 | 2019-02-26 | Univ Texas | método para tratar um distúrbio proliferativo e produto farmacêutico |
CA3018991A1 (en) | 2016-04-21 | 2017-10-26 | Bioventures, Llc | Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof |
CN109311871B (zh) | 2016-08-05 | 2020-02-28 | 密歇根大学董事会 | 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物 |
WO2019001383A1 (zh) | 2017-06-26 | 2019-01-03 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用 |
US11480568B2 (en) * | 2017-09-28 | 2022-10-25 | Yeda Research And Development Co. Ltd. | Diagnosis of autoimmune diseases |
EP3740487A4 (en) | 2018-01-10 | 2021-11-10 | Recurium IP Holdings, LLC | BENZAMIDE COMPOUNDS |
US10285998B1 (en) | 2018-04-04 | 2019-05-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
BR112020018978A2 (pt) | 2018-07-31 | 2021-03-02 | Ascentage Pharma (Suzhou) Co., Ltd. | produto de combinação que compreende um inibidor de bcl-2 e um inibidor de mdm2 e uso dos ditos inibidores na prevenção e/ou tratamento de câncer |
GEP20237460B (en) | 2018-07-31 | 2023-01-25 | Ascentage Pharma Suzhou Co Ltd | Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop |
EP3672595B1 (en) | 2018-07-31 | 2021-07-21 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
AU2019343044A1 (en) | 2018-09-18 | 2021-03-18 | Signalchem Lifesciences Corporation | Combination therapy for treating blood cancer |
EP3858832A4 (en) | 2018-10-29 | 2022-06-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2 SELECTIVE INHIBITOR |
CN113825754B (zh) | 2019-05-24 | 2023-09-22 | 正大天晴药业集团股份有限公司 | 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂 |
CN112707900B (zh) * | 2019-10-24 | 2022-06-10 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
CN113444078B (zh) * | 2020-03-25 | 2023-07-07 | 中国科学院上海有机化学研究所 | 抗凋亡蛋白Bcl-2抑制剂及其制备方法和应用 |
WO2021217051A1 (en) | 2020-04-24 | 2021-10-28 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates |
US20230174528A1 (en) | 2020-04-29 | 2023-06-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystal of trifluoromethyl/chloro disubstituted sulfonamide selective bcl-2 inhibitor |
EP4199924A1 (en) * | 2020-08-21 | 2023-06-28 | Ascentage Pharma (Suzhou) Co., Ltd. | Compositions and methods for treating systemic lupus erythematosus |
WO2022216942A1 (en) | 2021-04-07 | 2022-10-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
WO2022253313A1 (zh) | 2021-06-04 | 2022-12-08 | 正大天晴药业集团股份有限公司 | 三氟甲基取代的磺酰胺类化合物的磷酸酯 |
IT202100025976A1 (it) | 2021-10-06 | 2023-04-06 | Univ Degli Studi Di Perugia | Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1) |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2128208A (en) | 1937-02-27 | 1938-08-23 | Du Pont | Alkoxy derivatives of methacrylic acid esters and method of producing them |
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
PT1019385E (pt) | 1995-09-15 | 2004-06-30 | Upjohn Co | N-oxidos de aminoaril-oxazolidinona |
CN1300173C (zh) | 1996-02-09 | 2007-02-14 | 艾博特生物技术有限公司 | 结合人TNFα的人抗体 |
US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
CA2336714A1 (en) | 1998-07-06 | 2000-01-13 | Bristol-Myers Squibb Company | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
CA2338328A1 (en) * | 1998-07-21 | 2000-02-03 | Thomas Jefferson University | Small molecule inhibitors of bcl-2 proteins |
DE19913692A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
DE19929361A1 (de) | 1999-06-25 | 2001-01-04 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
US6787534B2 (en) | 1999-12-28 | 2004-09-07 | Eisai Co., Ltd. | Sulfonamide-containing heterocyclic compounds |
US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
US20020055631A1 (en) | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
HUP0400114A3 (en) | 2001-06-06 | 2007-05-02 | Lilly Co Eli | N-benzoyl-benzenesulfonamid derivatives as antitumor agents and pharmaceutical compositions containing them |
GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
US20090247613A1 (en) | 2002-02-20 | 2009-10-01 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
KR20040086452A (ko) | 2002-02-26 | 2004-10-08 | 아스트라제네카 아베 | 항암 화합물 zd1839의 신규한 결정질 형태 |
EP1480679B1 (en) | 2002-02-26 | 2007-05-23 | Astrazeneca AB | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
FR2836914B1 (fr) | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
JO2479B1 (en) | 2002-04-29 | 2009-01-20 | ميرك شارب اند دوم ليمتد | Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine |
JP4336678B2 (ja) | 2003-09-04 | 2009-09-30 | 株式会社日立超エル・エス・アイ・システムズ | 半導体装置 |
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
US7790190B2 (en) | 2004-03-20 | 2010-09-07 | Yasoo Health, Inc. | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
ES2294494T3 (es) | 2004-04-19 | 2008-04-01 | Symed Labs Limited | Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados. |
DE602004020812D1 (de) | 2004-07-20 | 2009-06-04 | Symed Labs Ltd | Neue zwischenprodukte für linezolid und verwandte verbindungen |
US20060078617A1 (en) | 2004-08-27 | 2006-04-13 | Fritz Schueckler | Pharmaceutical compositions for the treatment of cancer |
EP1804823A4 (en) | 2004-09-29 | 2010-06-09 | Amr Technology Inc | NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS |
US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
MX2007014049A (es) | 2005-05-12 | 2008-02-11 | Abbott Lab | Activadores de apoptosis. |
CA2608333A1 (en) | 2005-05-16 | 2006-11-23 | Irm Llc | Pyrrolopyridine derivatives as protein kinase inhibitors |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
PL1893612T3 (pl) | 2005-06-22 | 2012-01-31 | Plexxikon Inc | Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej |
US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
CA2631760A1 (en) | 2005-12-02 | 2007-06-07 | Robert A. Brodsky | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
EP1880715A1 (en) | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
CA2662320C (en) | 2006-09-05 | 2014-07-22 | Abbott Laboratories | Bcl inhibitors treating platelet excess |
US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
US20080182845A1 (en) | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
CN101616902B (zh) | 2007-02-15 | 2013-03-27 | 弗·哈夫曼-拉罗切有限公司 | 作为taar1配体的2-氨基*唑啉类化合物 |
WO2008124878A1 (en) | 2007-04-13 | 2008-10-23 | Cryptopharma Pty Ltd | Non-steroidal compounds |
CA2686545C (en) | 2007-04-19 | 2010-11-02 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
CN101842362A (zh) * | 2007-09-27 | 2010-09-22 | 沃尔特及伊莱萨霍尔医学研究院 | 苯并噻唑化合物 |
MX2010003548A (es) * | 2007-10-01 | 2010-06-02 | Univ Johns Hopkins | Metodos para el tratamiento de padecimientos neurologicos autoinmunes con ciclofosfamida. |
EP2197957A1 (en) | 2007-10-01 | 2010-06-23 | Arkema, Inc. | Blends of biodegradable polymers and acrylic copolymers |
JP2010540635A (ja) | 2007-10-02 | 2010-12-24 | コンサート ファーマシューティカルズ インコーポレイテッド | ピリミジンジオン誘導体 |
US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
WO2009051782A1 (en) | 2007-10-18 | 2009-04-23 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
WO2009052443A1 (en) * | 2007-10-19 | 2009-04-23 | Burnham Institute For Medical Research | Naphthalene-based inhibitors of anti-apoptotic proteins |
EP2217548A1 (en) | 2007-10-26 | 2010-08-18 | Concert Pharmaceuticals Inc. | Deuterated darunavir |
RU2472509C2 (ru) | 2007-11-16 | 2013-01-20 | Эбботт Лэборетриз | Способ лечения артрита |
WO2009073835A1 (en) | 2007-12-06 | 2009-06-11 | Abbott Laboratories | Oral compositions of abt-263 for treating cancer |
CN101481363B (zh) * | 2008-01-10 | 2011-05-04 | 江苏豪森药业股份有限公司 | 一种制备瑞格列奈的方法 |
CN101970655B (zh) | 2008-01-15 | 2014-03-05 | Abbvie公司 | 改良哺乳动物表达载体及其用途 |
US20090258914A1 (en) * | 2008-04-15 | 2009-10-15 | Burnham Institute For Medical Research | Inhibitor of Anti-Apoptotic Proteins |
NZ592719A (en) | 2008-10-07 | 2012-09-28 | Astrazeneca Uk Ltd | PHARMACEUTICAL FORMULATION 514 comprising 4-[3-( 4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
LT2376480T (lt) * | 2008-12-05 | 2016-09-12 | Abbvie Inc. | Sulfonamido dariniai kaip bcl-2-selektyviąją apoptozę sukeliantys agentai, skirti vėžio ir imuninių ligų gydymui |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US8586754B2 (en) * | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
WO2010077740A2 (en) | 2008-12-09 | 2010-07-08 | Cytokine Pharmasciences, Inc. | Novel antiviral compounds, compositions, and methods of use |
WO2010072734A2 (en) | 2008-12-23 | 2010-07-01 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Targeting prodrugs and compositions for the treatment of gastrointestinal diseases |
SG193849A1 (en) | 2009-01-19 | 2013-10-30 | Abbott Lab | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
RU2538965C2 (ru) | 2009-01-19 | 2015-01-10 | Эббви Инк. | Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний |
US20100297194A1 (en) | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
SG10201704742YA (en) | 2009-05-26 | 2017-07-28 | Abbvie Ireland Unlimited Co | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
TWI471321B (zh) | 2009-06-08 | 2015-02-01 | Abbott Gmbh & Co Kg | Bcl-2族群抑制劑之口服醫藥劑型 |
TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
CA2811805A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
CN103402521B (zh) * | 2010-11-23 | 2016-01-20 | 艾伯维巴哈马有限公司 | 使用选择性的bcl-2抑制剂的治疗方法 |
CN107266435A (zh) | 2010-11-23 | 2017-10-20 | Abbvie 公司 | 细胞凋亡诱导剂的盐和晶形 |
-
2011
- 2011-11-22 CN CN201180065747.XA patent/CN103402521B/zh not_active Expired - Fee Related
- 2011-11-22 ES ES11793928.0T patent/ES2603129T3/es active Active
- 2011-11-22 UA UAA201607110A patent/UA119150C2/uk unknown
- 2011-11-22 TW TW100142779A patent/TWI535701B/zh not_active IP Right Cessation
- 2011-11-22 SG SG2013040167A patent/SG190399A1/en unknown
- 2011-11-22 NZ NZ708508A patent/NZ708508A/en not_active IP Right Cessation
- 2011-11-22 RS RS20161159A patent/RS55545B1/sr unknown
- 2011-11-22 LT LTEP11793928.0T patent/LT2642999T/lt unknown
- 2011-11-22 CA CA2820618A patent/CA2820618C/en not_active Expired - Fee Related
- 2011-11-22 PL PL11793928T patent/PL2642999T3/pl unknown
- 2011-11-22 SG SG10201509631SA patent/SG10201509631SA/en unknown
- 2011-11-22 JP JP2013541010A patent/JP5876067B2/ja not_active Expired - Fee Related
- 2011-11-22 UA UAA201307893A patent/UA113157C2/uk unknown
- 2011-11-22 AR ARP110104338A patent/AR083946A1/es unknown
- 2011-11-22 MY MYPI2013700925A patent/MY165884A/en unknown
- 2011-11-22 TW TW105100832A patent/TWI620736B/zh not_active IP Right Cessation
- 2011-11-22 DK DK11793928.0T patent/DK2642999T3/en active
- 2011-11-22 UY UY0001033746A patent/UY33746A/es not_active Application Discontinuation
- 2011-11-22 MY MYPI2017000882A patent/MY191300A/en unknown
- 2011-11-22 EP EP16153335.1A patent/EP3028702B1/en active Active
- 2011-11-22 SI SI201131050A patent/SI2642999T1/sl unknown
- 2011-11-22 CN CN201610007260.0A patent/CN105664164B/zh not_active Expired - Fee Related
- 2011-11-22 PT PT117939280T patent/PT2642999T/pt unknown
- 2011-11-22 EP EP11793928.0A patent/EP2642999B1/en active Active
- 2011-11-22 NZ NZ610746A patent/NZ610746A/en not_active IP Right Cessation
- 2011-11-22 KR KR1020197027331A patent/KR20190109590A/ko active Application Filing
- 2011-11-22 ES ES16153335T patent/ES2701603T3/es active Active
- 2011-11-22 AU AU2011332000A patent/AU2011332000B2/en not_active Ceased
- 2011-11-22 HU HUE11793928A patent/HUE031267T2/en unknown
- 2011-11-22 KR KR1020187007228A patent/KR20180030257A/ko active Application Filing
- 2011-11-22 RU RU2013128544/14A patent/RU2593231C2/ru active
- 2011-11-22 US US13/301,898 patent/US20120129853A1/en not_active Abandoned
- 2011-11-22 BR BR112013012854-2A patent/BR112013012854B1/pt not_active IP Right Cessation
- 2011-11-22 MX MX2013005849A patent/MX346201B/es active IP Right Grant
- 2011-11-22 WO PCT/US2011/061769 patent/WO2012071374A1/en active Application Filing
- 2011-11-22 KR KR1020137016217A patent/KR101841084B1/ko active IP Right Grant
-
2013
- 2013-05-16 ZA ZA2013/03589A patent/ZA201303589B/en unknown
- 2013-05-21 IL IL226490A patent/IL226490A/en active IP Right Grant
- 2013-05-22 GT GT201300136A patent/GT201300136A/es unknown
- 2013-05-22 CL CL2013001458A patent/CL2013001458A1/es unknown
- 2013-06-07 CR CR20130268A patent/CR20130268A/es unknown
- 2013-06-21 EC ECSP13012710 patent/ECSP13012710A/es unknown
-
2014
- 2014-11-06 US US14/535,070 patent/US9345702B2/en active Active
-
2016
- 2016-01-19 JP JP2016007618A patent/JP6215368B2/ja not_active Expired - Fee Related
- 2016-04-22 US US15/136,582 patent/US9872861B2/en active Active
- 2016-05-20 PH PH12016500939A patent/PH12016500939B1/en unknown
- 2016-06-27 AU AU2016204396A patent/AU2016204396B2/en not_active Ceased
- 2016-12-13 CY CY20161101289T patent/CY1118442T1/el unknown
- 2016-12-21 HR HRP20161762TT patent/HRP20161762T1/hr unknown
-
2017
- 2017-03-03 DO DO2017000056A patent/DOP2017000056A/es unknown
- 2017-04-20 IL IL251845A patent/IL251845B/en active IP Right Grant
- 2017-12-12 US US15/838,605 patent/US20180369250A1/en not_active Abandoned
-
2019
- 2019-05-17 US US16/415,515 patent/US20200222413A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR083946A1 (es) | Metodos de tratamiento con inhibidores selectivos de bcl-2 | |
AR098912A1 (es) | Inhibidores de syk | |
SV2016005328A (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
AR101177A1 (es) | Inhibidores de la syk | |
AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
CO6700838A2 (es) | Compuestos sustituidos de banzamida | |
CO6321289A2 (es) | Compuestos de ester boronato y composiciones farmaceuticas de los mismos | |
EA201490453A1 (ru) | Замещенные аналоги (e)-n-(1-фенилэтилиден)бензогидразида в качестве ингибиторов деметилазы гистонов | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
AR059338A1 (es) | N-fenilbenzotriazolilo como inhibidores de c-kit | |
AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
AR094929A1 (es) | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 | |
AR085607A1 (es) | Inhibidores de la mst1 quinasa y metodos para su utilizacion | |
AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
RU2015125591A (ru) | БЕНЗИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ КАК МОДУЛЯТОРЫ RORc | |
AR097866A1 (es) | Derivados de 4-azaindol | |
AR083694A1 (es) | USO DE COMPUESTOS FARMACEUTICOS ACTIVOS PARA EL TRATAMIENTO DE ESTADOS PATOLOGICOS DEL SISTEMA NERVIOSO CENTRAL, COMPOSICION FARMACEUTICA, MODULADOR ALOSTERICO NEGATIVO DEL GABA A a5, METODO | |
AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
AR097199A1 (es) | Inhibidores de rorc2 y sus métodos de uso | |
AR084152A1 (es) | Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc | |
AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
AR077080A1 (es) | Compuestos de 2,3-dihidro-1h-indeno |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |